Every material Form 8-K ANI Pharmaceuticals has filed with the SEC since May 20, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ANI Pharmaceuticals entered a 364-day senior bridge credit facility of up to $676 million with JPMorgan Chase Bank, N.A. as administrative agent. The facility will be used to finance its recommended public cash offer for Egetis Therapeutics shares, convertible loan and warrants, valued at about SEK 5.6 billion, or approximately $559.9 million, and to refinance ANI's existing term loans and some Egetis debt, which adds significant borrowing and secured obligations for ANI shareholders.
Facility allows borrowings up to $676 million and matures 364 days after initial funding
Initial margin of 1.75% for ABR loans and 2.75% for adjusted term SOFR loans
Offer price is SEK 11.25 per Egetis share; total value about SEK 5.6 billion, or $559.9 million
Completion requires holders of at least 90% of Egetis shares (fully diluted) to tender and regulatory clearances; undertakings covering 42.2% of shares expire if the offer is not declared unconditional by March 31, 2027
ANI Pharmaceuticals reported third quarter 2026 net revenues of $290.8 million, up 27.6%, and GAAP diluted earnings per share of $1.51 versus $1.13 a year earlier. It cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million from $520 million to $540 million, citing slower-than-expected conversion of demand into patients, while raising its adjusted EBITDA and adjusted EPS guidance, and it announced a recommended offer to acquire Egetis Therapeutics.
Q3 2026 Cortrophin Gel net revenues were $138.7 million, up 36.1%, while Brands revenue fell 6.5% to $10.0 million.
2026 Cortrophin Gel revenue guidance was revised to $480 million to $500 million, down from $520 million to $540 million; total company revenue guidance was narrowed to $1,085 million to $1,125 million.
Adjusted non-GAAP EBITDA guidance was raised to $290 million to $300 million, and adjusted non-GAAP diluted EPS guidance was raised to $9.37 to $9.71.
The Egetis offer is SEK 11.25 per share, valued at approximately $560 million including incentive programs; the acceptance period is expected to run from about November 20, 2026 to December 18, 2026.
ANI Pharmaceuticals appointed Henry Gosebruch, former AbbVie strategy chief and former Neumora CEO, as a director effective August 19, 2026. Director Muthusamy Shanmugam resigned from the board on August 23, 2026, but remains an executive as Head of R&D and Chief Operating Officer of New Jersey Operations. The filing describes Gosebruch's role as supporting business development and capital allocation, which is relevant to shareholders as the company pursues its Rare Disease transformation.
Henry Gosebruch, 53, appointed to the Board with a term expiring at the 2027 annual meeting
Initial restricted stock award with a grant date fair value of $525,000, vesting in three equal annual installments
Samy Shanmugam resigned as a director effective immediately on August 23, 2026, and stays in his executive role
ANI Pharmaceuticals reported second-quarter 2026 total net revenues of $266.0 million, up 25.9% from a year earlier, and GAAP net income available to common shareholders of $24.7 million, or $1.05 per diluted share, versus $0.36 in the prior-year quarter. The company reaffirmed its full-year total net revenue guidance of $1,080 million to $1,140 million and adjusted non-GAAP EBITDA guidance of $285 million to $300 million, but lowered its Cortrophin Gel net revenue guidance to $520 million to $540 million from $540 million to $575 million, which matters because Cortrophin Gel is the company's largest product.
Total net revenues were $266.0 million in Q2 2026, up from $211.4 million in Q2 2025.
Diluted GAAP EPS was $1.05 versus $0.36; adjusted non-GAAP diluted EPS was $2.21 versus $1.80.
Cortrophin Gel 2026 net revenue guidance was revised to $520 million to $540 million from $540 million to $575 million; total net revenue guidance of $1,080 million to $1,140 million was reaffirmed.
The board authorized a share repurchase program of up to $100.0 million in common stock through May 2029, effective May 8, 2026.
At its 2026 Annual Meeting on May 21, 2026, ANI Pharmaceuticals stockholders elected seven directors, ratified Ernst & Young LLP as the independent auditor for fiscal 2026, approved executive pay on an advisory basis, and approved the Amended and Restated 2022 Stock Incentive Plan. The company will hold advisory votes on executive pay every year, following the stockholders' frequency vote. The filing covers governance matters only and includes no financial results or guidance.
Amended 2022 Stock Incentive Plan approved: 13,806,050 for, 1,080,387 against, 9,388 abstain, 2,030,222 broker non-votes
Advisory say-on-pay proposal approved: 13,819,988 for and 1,058,460 against
Stockholders voted 14,412,299 for an annual advisory pay vote; the board will hold these votes every one year
Ernst & Young LLP ratified as auditor for fiscal year ending December 31, 2026: 16,874,103 for and 7,333 against
ANI Pharmaceuticals reported first quarter 2026 revenue of $237.5 million, up 20.5% from a year earlier, and GAAP net income of $29.5 million, or $1.28 per diluted share, compared with $0.69 a year earlier. The company raised its 2026 total net revenue, adjusted EBITDA and adjusted diluted EPS guidance and authorized a $100 million share repurchase program.
Q1 2026 total net revenues of $237.5 million, up 20.5%; Cortrophin Gel net revenues of $75.1 million, up 42.1%
GAAP diluted EPS of $1.28 vs. $0.69 a year earlier; adjusted non-GAAP diluted EPS of $2.05 vs. $1.70
2026 total net revenue guidance raised to $1,080 million to $1,140 million from $1,055 million to $1,115 million; adjusted non-GAAP EBITDA raised to $285 million to $300 million
Board authorized a $100 million share repurchase program effective May 8, 2026, running through May 2029; Brands net revenues fell 50.9%
ANI Pharmaceuticals reported record fourth-quarter and full-year 2025 results, with Q4 net revenue of $247.1 million and GAAP net income available to common shareholders of $27.5 million, compared with a loss in the prior-year quarter. The company reaffirmed its full-year 2026 guidance, including total net revenue of $1,055 million to $1,115 million, which matters to shareholders as a reaffirmation rather than a change in outlook.
Q4 2025 net revenue was $247.1 million, up 29.6%; Cortrophin Gel rose 87.6% to $111.4 million, while Brands fell 37.9% to $12.3 million
Q4 GAAP diluted EPS was $1.18 versus a loss of $0.55 a year earlier; adjusted non-GAAP diluted EPS was $2.33 versus $1.63
Full-year 2025 net revenue was $883.4 million, up 43.8%, with GAAP net income available to common shareholders of $77.2 million
2026 guidance reaffirmed: total net revenue $1,055 million to $1,115 million and adjusted non-GAAP diluted EPS $8.83 to $9.34
ANI Pharmaceuticals said preliminary, unaudited 2025 results are within or above its prior guidance, with Cortrophin Gel net revenues up 76% for the year. It also issued 2026 guidance calling for total net revenues of $1.055 billion to $1.115 billion and adjusted non-GAAP diluted EPS of $8.83 to $9.34, and said the 2025 figures may change materially before the audit is complete.
Preliminary 2025 total net revenues are expected to be within or above $854 million to $873 million, adjusted non-GAAP EBITDA $221 million to $228 million, and adjusted non-GAAP diluted EPS $7.37 to $7.64.
Cortrophin Gel net revenues were approximately $347.8 million for 2025, up 76% year over year, and approximately $111.4 million for the fourth quarter, up 88%.
2026 guidance: total net revenues $1.055 billion to $1.115 billion, adjusted non-GAAP EBITDA $275 million to $290 million, and adjusted non-GAAP diluted EPS $8.83 to $9.34.
The company had approximately $285 million in unrestricted cash and cash equivalents as of December 31, 2025; the company plans to report full 2025 results in late February.
ANI Pharmaceuticals said Chairman Patrick Walsh has stepped down from the chair role and will not seek re-election at the 2026 Annual Meeting, remaining a director until then. The Board elected director Thomas Haughey as Chairman, and Jeanne Thoma replaced him as chair of the Audit and Finance Committee. The filing describes the change as a planned board transition, not one tied to any disagreement with the Board or management.
Patrick D. Walsh notified the company on November 24, 2025 that he will not seek re-election as a director at the 2026 Annual Meeting of Stockholders.
Thomas J. Haughey, a board member since May 2018, was unanimously elected Chairman of the Board.
Jeanne A. Thoma replaced Haughey as chair of the Audit and Finance Committee; Haughey remains a committee member.
ANI Pharmaceuticals filed an updated investor presentation that restates its third-quarter 2025 results, with total revenue of $228 million, up 54% year over year, and adjusted diluted EPS of $2.04, up 52%. The presentation says the company raised its full-year 2025 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, with the guidance issued on November 7, 2025. For shareholders, the higher outlook is a positive signal, although ILUVIEN revenue was pressured and the profit figures are non-GAAP measures.
Q3 2025 total revenue was $228 million, up 54% year over year; adjusted non-GAAP EBITDA was $60 million, up 70%; adjusted non-GAAP diluted EPS was $2.04, up 52%.
Full-year 2025 net revenue guidance is $854 million to $873 million, up from a previous $818 million to $843 million.
Full-year 2025 adjusted non-GAAP EBITDA guidance is $221 million to $228 million (previously $213 million to $223 million), and adjusted non-GAAP diluted EPS guidance is $7.37 to $7.64 (previously $6.98 to $7.35).
Q3 2025 ILUVIEN revenue was $17 million, which the company said was pressured by reduced access for Medicare patients and remaining YUTIQ units at physician offices.
ANI Pharmaceuticals reported third-quarter 2025 net revenues of $227.8 million, up 53.6% from a year earlier, and GAAP net income attributable to common shareholders of $26.3 million, or $1.13 per diluted share, compared with a loss of $1.27 per share in the prior-year quarter. The company raised its full-year 2025 total net revenue guidance to $854 million to $873 million and its adjusted non-GAAP EBITDA guidance to $221 million to $228 million, which points to higher expected results for shareholders.
Q3 2025 net revenues were $227.8 million, up 53.6% from $148.3 million in Q3 2024.
Cortrophin Gel net revenues were $101.9 million, up 93.8% year over year.
GAAP diluted EPS was $1.13 versus a loss of $1.27 a year earlier; adjusted non-GAAP diluted EPS was $2.04.
2025 total net revenue guidance was raised to $854 million to $873 million, from $818 million to $843 million; ILUVIEN net revenue was $16.6 million in the quarter, which the company said was pressured by reduced Medicare access.
ANI Pharmaceuticals furnished an updated investor presentation as Exhibit 99.1 for use at the H.C. Wainwright and Morgan Stanley healthcare conferences on September 8 and 9, 2025. The deck restates figures from the company's August 8, 2025 earnings release and does not report new full-year results, and the company says it is not reconfirming that guidance as of the presentation date.
Presentations at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.
Deck restates 2025 guidance issued August 8, 2025: net revenue $818 million to $843 million and adjusted non-GAAP EBITDA $213 million to $223 million.
Deck cites Q2 2025 total revenue of $211 million, up 53% year over year, and Q2 adjusted non-GAAP EBITDA of $54 million.
The company states it is not reconfirming the August 8 guidance and assumes no obligation to update it.
ANI Pharmaceuticals reported second-quarter 2025 net revenues of $211.4 million, up 53.1% from a year earlier, and GAAP net income available to common shareholders of $8.1 million, or $0.36 per diluted share, compared with a loss of $0.14 per share in the prior-year period. The company raised its full-year 2025 guidance for net revenues to $818 million to $843 million and adjusted non-GAAP diluted EPS to $6.98 to $7.35.
Q2 2025 net revenues were $211.4 million, up 53.1% year over year, or 37.0% on an organic basis excluding the Alimera acquisition.
Cortrophin Gel net revenues were $81.6 million, up 66.0% year over year.
GAAP diluted EPS was $0.36 versus a loss of $0.14 a year earlier; adjusted non-GAAP diluted EPS was $1.80 versus $1.02.
Full-year 2025 net revenue guidance was raised to $818 million to $843 million from $768 million to $793 million.
ANI Pharmaceuticals said it expects combined ILUVIEN and YUTIQ net revenues of $22.3 million for the quarter ended June 30, 2025. The figures are preliminary and unaudited, and the filing gives no prior-year comparison. The company also reported that the primary endpoint of its NEW DAY trial of ILUVIEN for diabetic macular edema was not met, though a secondary endpoint was met.
Preliminary, unaudited combined ILUVIEN and YUTIQ net revenues of $22.3 million for the three months ended June 30, 2025; results not yet reviewed by auditor EisnerAmper LLP
NEW DAY primary endpoint not met: 2.4 vs. 2.5 mean supplemental aflibercept injections (p=0.756)
Secondary endpoint met: mean time to first supplemental aflibercept injection of 185.4 days for ILUVIEN vs. 132.8 days for aflibercept (p<0.001)
Post-hoc analysis in a subset without major protocol deviations showed 1.8 vs. 2.5 injections (p=0.029); results presented July 23, 2025 at the ASRS meeting with a conference call at 8:30 am ET
ANI Pharmaceuticals filed its investor presentation for the Jefferies Global Healthcare Conference, where CEO Nikhil Lalwani will speak on June 4, 2025. The slides restate 2025 guidance issued on May 9, 2025, which the company describes as its second guidance raise of the year, and they report first-quarter 2025 revenue and profit growth. The filing presents previously disclosed figures rather than new results, but the guidance increase is relevant to shareholders.
2025 net revenue guidance is $768 million to $793 million, up from $756 million to $776 million previously.
2025 adjusted non-GAAP EBITDA guidance is $195 million to $205 million, up from $190 million to $200 million; adjusted diluted EPS guidance is $6.27 to $6.62, up from $6.12 to $6.49.
First-quarter 2025 total revenue was $197 million, up 43% year over year, and adjusted non-GAAP EBITDA was $51 million, up 35%.
Q1 ILUVIEN and YUTIQ revenue of $16 million was temporarily affected by factors the company listed, including sales force turnover; the company said demand accelerated in Q2 2025.
At its annual meeting on May 22, 2025, ANI Pharmaceuticals stockholders approved raising authorized common stock from 33,333,334 shares to 66,000,000 shares, effective on filing with the Delaware Secretary of State that day. They also elected eight directors and approved amended 2022 stock incentive and 2016 employee stock purchase plans. The filing does not say how the additional authorized shares will be used, but the increase gives the company room to issue more stock than before.
Authorized common shares increased from 33,333,334 to 66,000,000; the vote was 17,950,106 for and 461,824 against.
All eight director nominees were elected, with Renee P. Tannenbaum receiving the most against votes at 1,368,462.
Amended 2022 Stock Incentive Plan approved with 15,056,885 for and 1,202,893 against.
Advisory say-on-pay proposal approved with 14,565,587 for and 1,689,477 against.
ANI Pharmaceuticals filed an investor presentation for the H.C. Wainwright BioConnect conference on May 20, 2025, where CEO Nikhil Lalwani is scheduled to present. The deck restates the revised full-year 2025 guidance issued May 9, 2025, which raised net revenue to $768-793 million from $756-776 million and adjusted EBITDA to $195-205 million from $190-200 million, and describes this as the second guidance raise this year.
Full-year 2025 net revenue guidance is $768-793 million, up from $756-776 million; the deck calls this the second guidance raise in 2025.
Adjusted non-GAAP diluted EPS guidance is $6.27-6.62, up from $6.12-6.49.
Q1 2025 total revenue was $197 million, up 43% year over year; Q1 adjusted non-GAAP EBITDA was $51 million, up 35%.
CEO Nikhil Lalwani will present on May 20, 2025 at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ANI Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →